A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study will consist of 2 phases: Pretreatment Phase and Treatment Phase. The Pretreatment
Phase will have 2 time points: Screening and Baseline. Subjects will be admitted to the
clinical study ward the day before starting the study drug administration (Day -1) for PK and
safety assessments during Treatment Phase, and discharged at Day 33 (group A) and Day 47
(group B). Post-test will be done at Day 37 (+/-1), Day 42 (+3) (group A) and Day 51 (+/-1),
Day 56 (+3) (group B). Study medication will be administered with 240 mL of room temperature
water